Monday, July 01, 2024 5:32:56 AM
Saturday's Annual General Meeting does not seem to have been well received, if one considers the reaction on the German trading venues to be relevant.
This is probably mainly due to the statements on the status of the approval procedure, because unfortunately nothing concrete could or would be reported here. According to a transcript from an iHub user, the company does not even seem to know whether this "150-day review process" (which, as described several times, takes much longer than 150 days after an accepted application for approval anyway) is now being used or not. In addition, further queries are expected from the licensing authority.
All in all, unfortunately, new uncertainties and my hopelessly optimistic assessment from the last posting, that one can now expect a decision on the application for approval at any time or that this will be made in the next three or four months, has probably proven to be wrong.
If I interpret the statements now, which, as I said, I only know second-hand from some iHub postings, three to four months of waiting time are more likely to be the best-case scenario and it is more likely to be late autumn or winter before the MHRA decision is likely to be made at the earliest. However, it is more likely that it will not be until next year.
But for the permanent optimists, this development should bring new reason to rejoice, as they can now add to it really cheaply. his is the view of a german NWBO-shareholder :
https://www.wallstreet-online.de/diskussion/1325306-1-10/nwbo-northwest-biotherapeutics-inc-paradigmenwechsel-biotech-phase-3-results#beitrag_76026310
Shareprice in Germany is down 12.5% at the time of this posting.
This is probably mainly due to the statements on the status of the approval procedure, because unfortunately nothing concrete could or would be reported here. According to a transcript from an iHub user, the company does not even seem to know whether this "150-day review process" (which, as described several times, takes much longer than 150 days after an accepted application for approval anyway) is now being used or not. In addition, further queries are expected from the licensing authority.
All in all, unfortunately, new uncertainties and my hopelessly optimistic assessment from the last posting, that one can now expect a decision on the application for approval at any time or that this will be made in the next three or four months, has probably proven to be wrong.
If I interpret the statements now, which, as I said, I only know second-hand from some iHub postings, three to four months of waiting time are more likely to be the best-case scenario and it is more likely to be late autumn or winter before the MHRA decision is likely to be made at the earliest. However, it is more likely that it will not be until next year.
But for the permanent optimists, this development should bring new reason to rejoice, as they can now add to it really cheaply. his is the view of a german NWBO-shareholder :
https://www.wallstreet-online.de/diskussion/1325306-1-10/nwbo-northwest-biotherapeutics-inc-paradigmenwechsel-biotech-phase-3-results#beitrag_76026310
Shareprice in Germany is down 12.5% at the time of this posting.
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
